Saturday 15 August 2026

The Pharmaletter

Orna Therapeutics

A biotech company developing a new class of fully engineered circular RNA (oRNA) therapeutics.

Company Overview

Want to Update your Company's Profile?


Latest Orna Therapeutics News

Former Legend Biotech chief to lead newco builder K2 Therapeutics
12 August 2026
Lilly signs Haisco drug discovery deal worth more than $3 billion
2 June 2026
Lilly adds to cell therapies with buy of Orna Therapeutics
9 February 2026
Orna and Simnova expand RNA therapy collaboration
17 January 2025
More Orna Therapeutics news >


Today's issue

Romvimza wins MHRA approval for use in adults to treat TGCT
Pharmaceutical
Romvimza wins MHRA approval for use in adults to treat TGCT
14 August 2026
Biotechnology
Skye Bioscience and Redx Pharma to merge
14 August 2026
Pharmaceutical
India’s Dr Reddy's accelerates expansion in Russian market of gynecological drugs
14 August 2026
Pharmaceutical
Russia faces serious decline in launches of new cancer drugs this year
14 August 2026
Pharmaceutical
FDA accelerated approval for BMS’ Zenbexus
14 August 2026
Biotechnology
Olema Oncology appoints Jason O’Byrne as CFO
14 August 2026
Pharmaceutical
NICE recommends ALK’s pediatric SLIT tabs for allergic rhinitis
14 August 2026




Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze